Biotech M&A Reaches $106 Billion in 2026 Amid Strong Momentum
Published on · Source: cnbc.com
AI Summary
Summarized by AI from the source belowGlobal biopharma M&A has reached $106 billion across 201 deals in 2026, positioning it for the strongest year since pre-COVID, according to PitchBook data. If the pace continues, total deal value could exceed $250 billion by year-end. The average deal value has increased to $527.3 million from $365 million in 2025, driven by strategic acquisitions. Major companies are focusing on 'bolt-on' deals in the $1 billion to $5 billion range, with GSK's $2.2 billion acquisition of RAPT Therapeutics exemplifying this trend.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
